Atypical antipsychotics for people with both schizophrenia and depression

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Furtado, Vivek A ^a   Srihari, V ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RETRACTED ARTICLE; REVIEW;

EID: 45149106283     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005377.pub2     Document Type: Review

References (108)

1. Alfredsson 1984 {published data only} Alfredsson G, Harnryd C, Wiesel FA. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology 1984;84:237-41. [MEDLINE: 20478469].
2. Emsley 2003 {published data only} Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. Journal of Psychopharmacology 2003;17(2):210-5.
3. Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. European Neuropsychopharmacology 2001;11(3):264.
4. Emsley RA, Raniwala J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (seroquel) and haloperidol in schizphrenic patients with a history of and a demonstrated partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology 2000;15:121-31.
5. Jasovic 1997 {published data only} Jasovic-Gasic M, Crnobaric C, Miljevic C. Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
6. Addington 2002 Addington D, Addington J, Patten S, Remington G, Moamai J. Sertraline for depression in remitted schizophrenia. 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1.
7. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for amajor depressive episode in patients with remitted schizophrenia. Journal of Clinical Psychopharmacology 2002;22(1):20-5. [MEDLINE: 21657241].
8. Addington DE, Addington J, Patten S, Remington GJ, Moamai J, Labelle A. Sertraline for depression in remitted schizophrenia. Schizophrenia Research 2001;49(1,2):219.
9. Addington DE, Addington JM, Patten SB, Remington GJ, Moamai J, Labelle A, Beauclair L. Sertraline for depression in remitted schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
10. Altamura 1999 Altamura AC, Cao A, LaCroce ML, Serri L, Soddu A, Laddomada A, Percudani M. Are atypical antipsychotics less depressogenic than typical compounds?. Journal of the European College of Neuropsychopharmacology 1999;9:S168. [MEDLINE: 20558631].
11. Ames 1996 Ames D, Wirshing WC, Marder SR, Hwang SS, German CA, Mintz J, Goldstein D. Risperidone vs haloperidol: relative liabilities for OCD and depression. 8th Biennial Winter Workshop on Schizophrenia; 1996 Mar 16-22; Crans Montana, Switzerland. 1996.
12. Conley 2001 Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001;158(5):765-74. [MEDLINE: 21229038].
13. Myers JE, Mahmoud R, Berry S, Conley RR. Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder. European Neuropsychopharmacology 2001;11(3):254.
14. Myers JE, Mahmoud RA, Berry SA, Conley RR. Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, USA. Marathon Multimedia, 2001.
15. Myers JE, Mahmoud RA, Berry SA, Conley RR. Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
16. Csernansky 2002 Csernansky JG, Mahmoud R, Brener R. A comparison of risperidone and haloperdol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002;346(1):16-22.
17. Myers J, Mahmoud R, Keith SJ, Csernansky JG. The long-term benefit of risperidone versus haloperidol for affective symptoms in schizophrenia and schizoaffective disorder. Schizophrenia Research 2001;49(1,2):240.
18. Myers J, Mahmoud R, Keith SJ, Csernansky JG. The long-term benefit of risperidone versus haloperidol for affective symptoms in schizophrenia and schizoaffective disorder. Schizophrenia Research 2001;49(1,2):240.
19. Myers J, Mahmoud R, Keith SJ, Csernansky JG. The long-term benefit of risperidone vs. haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico. 2000.
20. Myers JE, Mahmoud RA, Keith SJ, Csernansky JG. Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, USA. Marathon Multimedia, 2001.
21. Myers JE, Mahmoud RA, Keith SJ, Csernansky JG. Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
22. Daniel 1999 Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6 week placebo controlled trial. Ziprasidone Study Group. Neuropyschopharmacology 1999;20(5):491-505. [MEDLINE: 99208909].
23. Hou 2002 Hou Y, Di X. A clinical study of the assistant effect of fluoxetine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2002;12(6):342-3.
24. Huang 2003 Huang Y, Jiang N, Zhang X. A clinical study of flouxetine to treat depressive symptoms of schizophrenia patients. Health Psychology Journal 2003;7476(3):239-40.
25. Kasckow 2001 Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal of Geriatric Psychiatry 2001;16:1163-7. [MEDLINE: 21614961].
26. Kasckow JW, Thalassinos A, Carroll B, Zisook S, Jeste DV. Antidepressant augmentation of antipsychotics in chronically hospitalized inpatients with schizophrenia. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26; San Francisco, USA. 2001.
27. Kirli 1997 Kirli S, Aliskan M. A comparative study of sertraline vs. imipramine in post-psychotic depressive disorder of schizophrenia. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
28. Masciocchi 1974 Masciocchi A, Reitano S, Vanini M, Cicchetti V. Preliminary results of a controlled trial with sulpiride versus chlorimipramine in chronic schizophrenic patients with marked ideo-emotional poverty [Risultati preliminari di una prova controllata con sulpiride versus clorimipramina in pazienti schizofrenici cronici conmarcata sintomatologia deficitaria]. Rivista di Patologia Nervosa e Mentale 1974;95:47-52. [MEDLINE: 75027787].
29. Moyano 1975 Moyano CZ. A double-blind comparison of loxatine loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Diseases of The Nervous System 1975;n/a:301-4.
30. Mueller 2002 Mueller MJ, Wetzel H, Benkert O. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: An evaluation using confirmatory factor analysis. International Clinical Psychopharmacology 2002;17(5):249-61.
31. Muller MJ, Benkert O. Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
32. Muller MJ, Wetzel H, Benkert O. Differential treatment effects of amisulpride versus flupentixol on latent dimensions of depressive and negative symptoms in acute schizophrenia. Schizophrenia Research 1998;29(1,2):157. [MEDLINE: 78162829].
33. Müller MJ, Wetzel H, Benkert O. Depressive symptoms in acute psychotic disorders: evaluation methods and treatment strategies. 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland. 1998.
34. Müller MJ, Wetzel H, Benkert O. Latent dimensions of depressive and negative symptoms in acute schizophrenia: treatment effects of high dose amisulpride vs. flupentixol. 11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France. 1998.
35. Mulholland 2003 Cooper SJ, Mulholland C, Lynch G, Baynes D, King DJ. Sertraline in the treatment of depressive symptoms in stable, chronic schizophrenia: a placebo controlled trial. Schizophrenia Research 2000;41(1):209. [MEDLINE: 99171102].
36. Mulholland C, Lynch G, Cooper SJ, King DJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia. 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997.
37. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. Journal of Psychopharmacology 2003;17(1):107-12.
38. Muller 1998 Benkert O, Müller-Siecheneder F, Wetzel H. Negative and depressive symptoms in acute schizophrenic episodes- do they improve under neuroleptic treatment?. 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK. 1996.
39. Mueller MJ BO. Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics. European Neuropsychopharmacology 1997;7(Suppl 2):S227-8.
40. Muller MJ, Wetzel H, Benkert O. Differential treatment effects of amisulpride versus flupentixol on latent dimensions of depressive and negative symptoms in acute schizophrenia. Schizophrenia Research 1998;29(1,2):157. [MEDLINE: 78162829].
41. Muller Siecheneder F, Hillert A, Benkert O. Risperidone in the treatment of patients with a combined psychotic and depressive syndrome. Pharmacopsychiatry 1995;28:201. [MEDLINE: 96431333].
42. Muller Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. Journal of Clinical Psychopharmacology 1998;18(2):111-20. [MEDLINE: 98216434].
43. Murasaki 2000 Murasaki M, Koyama T, Yagi G, Ushijima S, Kamijima K. Efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S150.
44. Naber 1997 Naber D. Evidence of efficacy of neuroleptics in effective versus negative symptoms. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
45. Nurowska 1980 Nurowska K. Clinical evaluation of sulpiride [Ocena kliniczna sulpirydu]. Psychiatria Polska 1980;14(1):37-42. [MEDLINE: 80167627].
46. Peuskens 2002 Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbation of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997;132:396-401.
47. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W, Amisulpride Study Group. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychhiatry Research 1999;88:107-17.
48. Peuskens J, Möller H-J. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology 2001;11(3):255.
49. Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology 2002;12:305-310. [MEDLINE: 22466396].
50. Rein 1997 Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. International Clinical Psychopharmacology 1997;12(Suppl 2):S19-27. [MEDLINE: 97361270].
51. Tollefson 1998 Alan B, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999;2:144.
52. Andersen SW, Tollefson GD, Sanger T. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA. 1999.
53. Andersen SW, Tollefson GD, Sanger TM. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Schizophrenia Research 1999;1,2 &3:269. [MEDLINE: 96431333].
54. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia. Biological Psychiatry 1999;45(4):403-11. [MEDLINE: 99171102].
55. Gilmore JA, Kinon BJ, Zhao Z, Barber B. Improvement in quality of life and depressive symptoms in schizophrenic patients is associated with robust acute treatment response of olanzapine versus haloperidol. Schizophrenia Research 2002;53(3 Suppl 1):177. [MEDLINE: 66109509].
56. Tollefson GD. A blinded trial on the course and relationship of depressive symptoms in schizophrenia. 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland. 1998.
57. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997;154(4):457-65. [MEDLINE: 97245663].
58. Tollefson GD, Lu Y. A blinded trial on the course and relationship of depressive symptoms in schizophrenia. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA. 1997.
59. Tollefson GD, Sanger TM. Anxious depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?. Schizophrenia Research 1999;35(Suppl):S13-21. [MEDLINE: 99206220].
60. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 1998;43(11):803-10. [MEDLINE: 98274603].
61. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry 1998;55(3):250-8.
62. Tollefson 1999 Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry 1999;60(Suppl 5):23-9; discussion 30.
63. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry 1999;46(3):365- 73. [MEDLINE: 99364060].
64. Tollefson GD, Sanger TM. A blinded trial on the course and relationship of depressive symptoms in schizophrenia. Schizophrenia Research 1998;29(1,2):205.
65. Zhao 2003 Zhao JS, Li YM, Zhou SB, A study on the efficacy of risperidone in the treatment of chronic schizophrenia with depression. Medical Journal of Chinese Civil Administration 2003;7473(5):263- 5.
66. Cantillon 1998 Cantillon M, Goldstein JM. Efficacy of quetiapine fumarate in affective symptoms of schizophrenia. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-June 4, Toronto, Canada. 1998.
67. Lee 2001 Lee M, Meltzer HY. Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia. 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1.
68. Martin 2002 Martin SD, Loo H, Peuskens J, Rein W, Fleurot O. A six-month, double-blind, controlled trial in schizophrenic patients comparing amisulpride and olanzapine. Preliminary results on short-term analysis. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S119.
69. Yagdiran 2000 Yagdiran O, Krausz M, =PERSIST. Depressive symptoms under atypical neuroleptic treatment in schizophrenia. Nervenarzt 2000;71(Suppl 1):S135-S136.
70. Yagdiran 2001 Yagdiran O, Moritz S, Haasen C, Krausz M. Depressive symptoms among patients with schizophrenia treated with atypical antipsychotics. European Neuropsychopharmacology 2001;11(3):244.
71. Fleurot 2002 Fleurot O, Martins S, Loo H, Peuskens J, Rein W. Amisulpride vs. olanzapine in schizophrenia. XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002.
72. Fleurot O, Martins S, Loo H, Peuskens J, Rein W. Amisulpride vs olanzapine in schizophrenia. Preliminary results on short-term analysis. European Psychiatry 2002;17(Suppl 1):107s.
73. Addington 1998 Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. British Journal of Psychiatry 1998;S172(33):90-2.
74. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
75. Berlin 1997 Berlin JA, Miles CG, Crigliano MD, Conill AM, Goldman DR, Horowitz DA. Does blinding of readers affect the results of meta-analyses? Results of a randomized trial. Online Journal of Current Clinical Trials 1997:205.
76. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315(7108):600.
77. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indises. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
78. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
79. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
80. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21(19): 2971-80.
81. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
82. Emsley 2003 Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. Journal of Psychopharmacology 2003;17(2):210-5.
83. Escamilla 2001 Escamilla MA. Diagnosis and treatment of mood disorders that cooccur with schizophrenia. Psychiatric Services 2001;52(7):911-9.
84. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
85. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
86. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
87. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005, Issue 3.
88. Kay 1986 Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda, NY: Mulit-Health Systems, 1986.
89. Knights 1981 Knights A, Hirsch SR. "Revealed" Depression and drug treatment for schizophrenia. Archives of General Psychiatry 1981;38(7):806-11.
90. Kramer 1989 Kramer MS, Vogel WH, DiJohnson C. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Archives of General Psychiatry 1989;46(10):922-8.
91. Levinson 1999 Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. American Journal of Psychiatry 1999;156(8):1138-48.
92. Lindenmayer 1991 Lindenmayer JP, Grochowski S, Kay SR. Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms. Comprehensive Psychiatry 1991;32(6):528-33.
93. Markou 1996 Markou P. Depression in schizophrenia: a descriptive study. Australian and New Zealand Journal of Psychiatry 1996;30(3):354-7.
94. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
95. Martin 1985 Martin RL, Cloninger CR, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. Journal of Clinical Psychiatry 1985;46(11 Pt 2):9-13.
96. Myers 2001 Myers JE, Thase ME. Risperidone: review of its therapeutic utility in depression. Psychopharmacology Bulletin 2001;35(4):109-29.
97. Overall 1962 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
98. Perenyi 1998 Perenyi A, Norman T, Hopwood M, Burrows G. Negative symptoms, depression, and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. Journal of Affective Disorders 1998;48(2-3):163-9.
99. Plasky 1991 Plasky P. Antidepressant usage in schizophrenia. Schizophrenia Bulletin 1991;17(4):649-57.
100. Rachid 2004 Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. Journal of Clinical Psychiatry 2004;65(11):1537- 45.
101. Roy 1986 Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatric Clinics of North America 1986;9(1):193-206.
102. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
103. Siris 2000 Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. American Journal of Psychiatry 2000;157(9):1379-89.
104. Tapp 2001 Tapp A, Kilzieh N, Wood AE, Raskind M, Tandon R. Depression in patients with schizophrenia during an acute psychotic episode. Comprehensive Psychiatry 2001;42(4):314-8.
105. Tollefson 1998 Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry 1998;55(3):250-8.
106. Tollefson 1999 Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry 1999;60(Suppl 5):23-9; discussion 30.
107. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
108. Whitehead 2003 Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychological Medicine 2003;33(4):589-99.